Novo Nordisk A/S Class B
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Maziar Mike Doustdar
- Full Time Employees
- 68,794
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Novo Alle 1 Bagsværd CR Denmark 2880
- IPO Date
- May 17, 1974
- Website
- novonordisk.com
- Similar Companies
- Business
- Novo Nordisk A/S is a global healthcare company headquartered in Bagsværd, Denmark, founded in 1923, specializing in the research, development, manufacture, and marketing of pharmaceutical products primarily focused on diabetes care, obesity, rare diseases, and biopharmaceuticals. Its main product portfolio includes diabetes and obesity care products such as insulin and GLP-1 receptor agonists (including the Ozempic and Wegovy brands); insulin delivery systems; and treatments for hemophilia, growth hormone therapy, and hormone replacement therapy. The company operates across more than 180 countries, with key markets in North America, Europe, and Asia. Recent major developments include the acquisition of cardiovascular disease-focused Cardior Pharmaceuticals and the Montreal-based biotech Inversago Pharma to expand its metabolic disorder pipeline, along with a $2.2 billion collaboration with US biotech Septerna to develop oral small molecule therapies for obesity, type 2 diabetes, and cardio-metabolic disorders. Novo Nordisk is advancing next-generation obesity drugs such as CagriSema, currently in phase 3 trials, which has demonstrated significant weight loss in clinical studies, as well as oral and injectable amycretin candidates targeting dual hormone pathways for enhanced weight management. The company has also received US and EU approvals for Alhemo® (Concizumab), for hemophilia treatment, and continues to invest substantially in R&D and production capacity to meet growing global demand, aiming to reinforce its leadership in diabetes, obesity, and emerging cardio-metabolic therapies while expanding into chronic kidney disease and metabolic dysfunction-associated steatohepatitis (MASH). Novo Nordisk’s strategic focus includes sustaining market share in GLP-1 segments, launching innovative treatments, and pursuing acquisitions and partnerships to strengthen its therapeutic areas and product offerings globally.
Company News
GLP-1 drugs help control prediabetes better than current standard medicine
2 Reasons for Hope From Novo Nordisk Earnings
Beleaguered Novo offers relief to investors, thanks to Wegovy pill
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
Novo Nordisk's CFO Karsten Munk Knudsen to leave company
Novo raises full-year outlook as Wegovy sales impress
Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
3 Dirt Cheap Dividend Stocks to Buy in November 2026
Novo Before Q3 Earnings: How Should Investors Play the Stock?
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs
Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Novo Has Big Plans for 2030. Should You Buy the Stock Now?
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
Novo Nordisk A/S $NVO Stock Sold by Evergreen Capital Management LLC
Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades